Skip to content

Author

B. Huffman

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

A Phase 1 Trial of Low-dose Gemcitabine Combined with ATR Inhibitor Elimusertib for Advanced Solid Tumors.

PURPOSE Preclinical data suggest that the anti-cancer efficacy of ATR inhibitors can be synergistically enhanced by low-dose gemcitabine. To test the clinical feasibility of this regimen, we conducted a phase 1 trial of low-dose gemcitabine combined with the ATR inhibitor elimusertib (BAY1895344). PATIENTS AND METHOD...

T. Jayakrishnan, Rebecca L. Porter, Alice P. Chen et al. · 0 citations
Sep 2026

Abstract A127: Targeting replication stress in pancreatic cancer: results of a phase 1b trial of azenosertib and gemcitabine in second line pancreatic cancer after progression on FOLFIRINOX

The combination of azenosertib and gemcitabine was associated with substantial myelosuppression in patients with metastatic PDAC previously treated with FOLFIRINOX, limiting further clinical evaluation of this dosing strategy.

B. Huffman, Haeseong Park, N. Jackson et al. · 0 citations
Open access Sep 2026

CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...

Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.